EXPRE-SON-REA : Expressive Own Names in Neurophysiologic Assessment of Comatose Patients (EXPRESONREA)
EXPRE-SON-REA : Expressive Versus Neutral Own Names in Neurophysiologic Prognosis Assessment of Intensive Care Unit Comatose Patients.
Evaluating the neurologic prognosis in disorders of consciousness (DOC) patients is still a crucial issue in intensive care units.
Neurophysiology allows the investigators to record cerebral responses of patients to auditory stimuli and in particularly to their own name. Numerous studies try to improve the relevance of the auditory stimuli used in this paradigm.
Here the investigators assess if the use of own name stimuli uttered by more expressive voices (for example smiling voices) modulates the cerebral responses recorded. They then correlate these cerebral responses to the neurologic prognosis at three months.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Late auditory evoked potentials (as P3 wave) are used in neurophysiology to assess the level of consciousness in DOC (disorder of consciousness) patients. The P3 wave, elicited by listening standard and deviant stimuli, corresponds to the activation of a frontoparietal network and is considered to reflect a cognitive attention task. Using the own name of the patient as deviant stimuli improve the ability to detect the P3 wave because of the particularly relevance of this stimulus for the patient. However the correlation of this P3 wave and neurologic prognosis is still imperfect and depends on the etiology of the DOC.
In human cognition, to identify the expressivity valence of a voice is essential. Neural processing of expressive voices involves more widespread brain areas than neutral voices processing.
Here the investigators assume that using own name stimuli uttered by more expressive voices (positive : smiling voice or negative : rough voice) should recruit more widespread brain areas and modulate the cerebral responses recorded. The investigators then evaluate if these cerebral responses are relevant markers of consciousness and correlate them to neurologic prognosis at three months.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Estelle Pruvost-Robieux, MD
- Numéro de téléphone: + 33 1 45 65 81 89
- E-mail: e.pruvost@ghu-paris.fr
Sauvegarde des contacts de l'étude
- Nom: Martine Gavaret, Professor
- Numéro de téléphone: + 33 1 45 65 81 89
- E-mail: m.gavaret@ghu-paris.fr
Lieux d'étude
-
-
-
Paris, France, 75014
- Recrutement
- GHU Paris Psychiatrie Neurosciences
-
Contact:
- Estelle Pruvost-Robieux, MD
- Numéro de téléphone: +33 1 45 65 81 89
- E-mail: e.pruvost@ghu-paris.fr
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age over 18
- Disorder of consciousness defined as :
Glasgow coma scale < 8 or >8 but
- eyes opening to pain only
- No response to basic command
- Available neuro-imagery (CT-scan or MRI)
- Normal temperature (no fever or hypothermia)
- Normal blood pressure during neurophysiologic evaluation
- Given consent from relatives
Exclusion Criteria:
- Brain death
- Known deafness
- Severe sepsis uncontrolled during neurophysiologic evaluation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Autre: Whole group
The whole group listen successively the 3 paradigms :
|
Evoked related potential are performed for each patient during listen to its own name uttered by i) a neutral voice ii) a smiling voice iii) a rough voice
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Positive predictive values of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices for the neuroprognosis at 3 months
Délai: 3 months from DOC evaluation
|
Determination of the positive predictive values of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Negative predictive values of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Délai: 3 months from DOC evaluation
|
Determination of the negative predictive values of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Sensitivity of P3a responses occurences to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Délai: 3 months from DOC evaluation
|
Determination of the sensibility of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
|
Specificity of P3a responses to own-names uttered by expressive voices (smiling and rough voices) and neutral voices at 3 months for the neuroprognosis at 3 months
Délai: 3 months from DOC evaluation
|
Determination of the specificity of the occurence of the P3a wave recorded with expressive and neutral voices for neuroprognostic assessment at 3 months (according to the GOS-E scale)
|
3 months from DOC evaluation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Negative predictive value of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Délai: 7, 14 and 28 days from DOC evaluation
|
Determination of the negative predictive value of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Positive predictive value of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Délai: 7, 14 and 28 days from DOC evaluation
|
Determination of the positive predictive value of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Sensitivity of P3a responses occurences uttered by expressive voices and neutral voices according to the CRS-r scale
Délai: 7, 14 and 28 days from DOC evaluation
|
Determination of the sensibility of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Specificity of P3a to own-name uttered by expressive voices and neutral voices according to the CRS-r scale
Délai: 7, 14 and 28 days from DOC evaluation
|
Determination of the specificity of P3a waves (present or absent) for neuroprognostic at 7 days, 14 days and 28 days (according to the CRS-r scale)
|
7, 14 and 28 days from DOC evaluation
|
|
Negative predictive value of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Délai: 3 months
|
Determination of the negative predictive value of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Positive predictive value of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Délai: 3 months
|
Determination of the positive predictive value of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Sensitivity of P3a responses occurences uttered by expressive voices and neutral voices according to eyes-opening
Délai: 3 months
|
Determination of the sensibility of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Specificity of P3a to own-name uttered by expressive voices and neutral voices according to eyes-opening
Délai: 3 months
|
Determination of the specificity of P3a waves (present or absent) for eyes-opening at 3 months
|
3 months
|
|
Description of the amplitudes of the P3a wave to own-name uttered by expressive voices versus neutral voices.
Délai: 3 months
|
Amplitudes of P3a waves recorded with own name uttered by expressive and neutral voices
|
3 months
|
|
Description of the latencies of the P3a wave to own-name uttered by expressive voices versus neutral voices.
Délai: 3 months
|
Latencies of P3a waves recorded with own name uttered by expressive and neutral voices
|
3 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2020-A00747-32
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .